Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210411005016/en/
Figure 1: Effect of TOTUM•854 supplementation on systolic (SBP) and diastolic (DBP) blood pressure after 3 weeks, in an induced hypertension model (L-NAME model). After 3 weeks, L-NAME induced a 24 mmHg-raise in SBP and a 19 mmHg- raise in DPB (grey bars). Supplementation with TOTUM•854 (blue bars) significantly reduced SBP by 16 mmHg (p<0.01) and DBP by 15 mmHg (p<0.05). (Graphic: Business Wire)
VALBIOTIS (FR0013254851 – ALVAL, PEA-SME eligible) (Paris:ALVAL), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the presentation of positive preclinical results of TOTUM•854 in hypertension at the joint meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) held from April 11 to 14, 2021, in virtual format.
This research, conducted on two different in vivo models, shows that TOTUM•854 prevents hypertension.
Based on this positive data, Valbiotis is stepping up its development of TOTUM•854 and will launch three clinical studies at the end of this year, including a Phase II/III clinical study for reduction of hypertension, a risk factor for cardiovascular disease.
TOTUM•854 could be commercialized at the end of this study, up to 3 years ahead of schedule, in partnership with a major healthcare player.
Pascal SIRVENT, Member of the Board and Head of Discovery, Preclinical and Translational Research at Valbiotis, said: “We are proud of this first selection at a major international congress in the cardiovascular field, for which Valbiotis has partnered with the University of Avignon. The TOTUM•854 data collected from two different models of hypertension is remarkable, it validates our hypotheses and our approach to this condition. This very strong proof-of-concept for prevention of hypertension points to ambitious clinical development for TOTUM•854.”
The work presented at the ESH-ISH Joint Meeting was conducted on a model of hypertension induced by L-NAME (a NO synthase inhibitor). In this classic model of hypertension, predictive of human physiology, TOTUM•854 prevented the onset of hypertension compared with the control group. Additional data, obtained from a polygenic model of hypertension (SHR, spontaneously hypertensive rats), also shows a positive effect of TOTUM•854 that delays the onset of hypertension. In addition, a significant acute effect was observed following a single dose of TOTUM•854 on the same SHR model.
Table 1: Effect of a single oral dose of TOTUM•854 in a polygenic model of hypertension (SHR model) on systolic (SBP) and diastolic (DBP) blood pressure, during 24 hours. Starting the experiment (« baseline »), SBP (164 mmHg) and DBP (115 mmHg) were typical of an installed hypertension. Oral intake of a TOTUM•854 dose led to blood pressure reduction, resulting in a decrease of both SBP and DBP Areas Under the Curve (AUC), over a 24h-record compared to the control group.
(mmHg; mean ± SEM)
Change in area under the curve over
164.4 ± 4.7
-108.0 ± 87.8
115.9 ± 3.6
-84.4 ± 69.3
These results stem in particular from a program carried out under a partnership between Valbiotis and the experimental unit of the Cardiovascular Pharm-Ecology Lab (LaPEC) of the University of Avignon, directed by Cyril REBOUL, PhD, expert in cardiovascular pharmacology.
Cyril REBOUL, PhD, head of the experimental unit of the Cardiovascular Pharm-Ecology Lab (LaPEC) of the University of Avignon, said: “Through our work, we have shown a preventive effect of TOTUM•854 on the development of hypertension in a recognized preclinical model using the L-NAME inhibitor. Undeniably, these results constitute quite an achievement at this stage of TOTUM•854’s development. We are very pleased to have been able to contribute our expertise as part of this fruitful partnership with Valbiotis.”
Acceleration of the development for commercialization now scheduled for 2023
Based on these results, Valbiotis has revised its clinical development program for TOTUM•854 with the launch of a Phase II/III study, the last step before a health claim application in Europe and the United States for reduction of blood pressure, a risk factor for cardiovascular disease. This international, multicenter, randomized, placebo-controlled study will be conducted in a population of 600 volunteers with mild to moderately elevated blood pressure. The study will involve three groups: a TOTUM•854 group at a dose of 3.75 g/day, a TOTUM•854 group at a dose of 2.5 g/day and a placebo group. Its primary endpoint will be the reduction of systolic blood pressure in the TOTUM•854 group (3.75 g/day) after 6 months of supplementation versus the placebo group. It will also evaluate the effect of a reduced dose of TOTUM•854 (2.5 g/day) on blood pressure. In addition, 24-hour ambulatory blood pressure measurements will be taken as a secondary endpoint of the study. The protocol is expected to be filed with the authorities in the fourth quarter of 2021, with results anticipated in the second half of 2023.
A second international, multicenter, randomized, placebo-controlled clinical study will be conducted in parallel at a dose of 3.75 g/day of TOTUM•854. This strategy will allow Valbiotis to prepare a complete health claim application.
Finally, Valbiotis will conduct a third clinical study to measure the bioavailability of TOTUM•854, characterize its metabolites and explore their mode of action.
Murielle CAZAUBIEL, Member of the Board, Head of Development and Medical Affairs at Valbiotis, said: “These preclinical results raise great hopes for the clinical development of TOTUM•854 in the prevention of hypertension. That’s why we are accelerating our strategy for this active substance. Hypertension is considered the foremost chronic disease in the world by the World Health Organization. It’s a serious risk factor for cardiovascular disease, in particular strokes. TOTUM•854 could quickly become an extremely interesting non-drug alternative for people at risk, whether or not they are already taking treatment. This plant-derived active substance would ultimately be developed in the form of capsules or powder for dilution.”
The new strategic development plan will leverage the potential of TOTUM•854 in preventing hypertension, with the aim of bringing it to market as soon as the Phase II/III study ends, in other words by 2023.
Market data on mild to moderate hypertension: conquering an addressable market of over one billion euros
In 2020, AEC Partners conducted a mild to moderate hypertension market study in the United States and 5 main European countries (Germany, Spain, France, Italy and the United Kingdom).
It highlights the size of this market in these regions, which alone represents 124 million people with moderately elevated blood pressure.
Sébastien PELTIER, CEO and Chairman of the Board, said: “In the US and 5 main European countries (Germany, Spain, France, Italy and the United Kingdom), our target represents 124 million people with mild to moderately high blood pressure. TOTUM•854 will give us access to a huge market worth over €1.15 billion. We are now embarking on a new cycle with the development of TOTUM•854 for prevention of hypertension. By accelerating our strategy, we will gain 3 years on our development plan, with a possible market launch on completion of the Phase II/III study. I am confident that we will achieve growth and create value for our shareholders over the long term, turning our innovations into products that can transform the lives of millions by addressing as yet unmet medical needs.”
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Corporate communication / Valbiotis
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
Financial communication / Actifin
+33 1 56 88 11 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EAG Expands Medical Device Testing Services with New Laboratory7.5.2021 18:22:00 EEST | Press release
EAG Laboratories is expanding its medical device testing capabilities with a new 20,000 square-foot laboratory located in St. Louis, Mo. The new laboratory is a bespoke design to support the requirements of the medical device industry. It increases EAG’s analytical capabilities, allows for improved turnaround times and helps meet evolving requirements from the FDA as well as the European Union Medical Device Regulations (MDR). Specialty features of the laboratory include: A cleanroom designed for particle isolation and identification A dedicated medical device polymer analysis laboratory State-of the-art instrumentation to support biocompatitility testing of ISO 10993-18 programs for medical devices and combination products EAG scientists have been investigating and resolving product failures for more than half a century and have a deep understanding of materials and testing procedures. The medical device laboratory expansion allows EAG to leverage that knowledge and apply it toward su
SoftServe Wins Learning and Development Honor at 2021 ATD Excellence in Practice Awards7.5.2021 14:00:00 EEST | Press release
SoftServe, a leading digital authority and consulting company, won the Excellence in Practice Award in the ‘Learning and Development’ category in the 2021 Association for Talent Development (ATD) Excellence in Practice Awards. SoftServe was recognized for its corporate learning hub, SoftServe University, which focuses on learning and development opportunities for associates, including the design and delivery of training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210507005003/en/ Association for Talent Development logo. (Photo: Business Wire) “SoftServe is dedicated to creating a people-centric organization that allows associates to grow and develop professionally,” said Galyna Datsiv, AVP of Learning and Development at SoftServe. “Our corporate learning ecosystem within the integrated talent management framework enables us to reach SoftServe’s strategic business goals by ensuring associates are qualified and have the ex
Monument Assurance Belgium and Intégrale Reach Agreement for the Transfer of Intégrale's Entire Portfolio and Staff to MAB7.5.2021 13:26:00 EEST | Press release
Monument Assurance Belgium (“MAB”) and Intégrale have reached an agreement under which MAB will acquire the entire portfolio and all the staff of the insurance company Intégrale. This agreement follows a firm offer from MAB, which was considered by the provisional administrators appointed by the National Bank of Belgium (“NBB”) to be that which best meets the interests of Intégrale policyholders and staff. The transaction remains subject to the final approval of the NBB. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210507005270/en/ During the transition period, MAB and Intégrale will take all steps necessary to prepare for a seamless transfer for policyholders, brokers and staff. In the meantime, Intégrale's staff will continue to service policyholders and brokers as usual. In addition to the transfer of assets at the time of closing, MAB will offer an 18-month employment guarantee to all employees and, in addition, a 3-mo
The Metals Company Joins European Industry Alliances to Bolster Battery Supply Chain for the Clean Energy Transition7.5.2021 11:00:00 EEST | Press release
Today, The Metals Company (formerly DeepGreen), a developer of the world’s largest and highest-grade estimated source of battery metals, announced it has joined two of the European Union’s foremost industrial alliances—the European Raw Materials Alliance (ERMA) and the European Battery Alliance (EBA)—as the bloc advances its plans to become a global leader in the sustainable production of the batteries necessary to store clean energy and power electric vehicles (EVs). As a member of these industrial alliances, The Metals Company—which announced in March its plans to go public via a merger with the Sustainable Opportunities Acquisition Corporation (NYSE: SOAC)—brings a new, scalable source of battery metals to the table in the form of polymetallic nodules found unattached on the deep seafloor in the Pacific Ocean, which can help deliver upon their mandate for a diverse, reliable and responsible supply of critical minerals needed for low-carbon technologies. Under its Green Deal, the Eur
Morocco and UN Celebrate First-Ever International Argan Tree Day7.5.2021 09:30:00 EEST | Press release
Morocco and the United Nations will be marking the first-ever International Argan Tree Day on May 10th, 2021. The Argan tree, a tree specific to the Kingdom of Morocco, will thus be celebrated every year on May 10, as an intangible cultural heritage of humanity and ancestral source of sustainable development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005652/en/ February 22, 2021: The United Nations’ General Assembly adopted by consensus a resolution proclaiming May 10 of each year as the “International Argan Tree Day” (Photo: AETOSWire) The proclamation of the International Argan Tree Day was announced on March 3, 2021, when the UN General Assembly adopted by consensus a draft resolution initiated by Morocco and hailed by all United Nations’ member states. This milestone is a culmination of Morocco’s quest to mobilize the international community to protect and further develop the country’s Argan industry. It is al
Tigo Energy Demonstrates Optimization to Installers in Brazil with Stark Renováveis Installation7.5.2021 03:14:00 EEST | Press release
Tigo Energy, Inc., the solar industry’s leading Flex MLPE (Module Level Power Electronics) supplier, announced today that Stark Renováveis has used the Tigo TS4-A-O to mitigate energy lost due to shade on their corporate headquarters in São José do Rio Preto, Brazil. Their confidence in Tigo’s solution drove the selection of the products for their own use. The Tigo solution gives installers and commercial system owners the freedom to choose their preferred inverters and panels along with the right features for optimized, monitored and PV safe systems. The Stark Renováveis team chose a rooftop PV system with 405 Wp modules organized in multiple strings and using GoodWeTM grid-tied inverters. The optimum placement of the modules was on a roof bordering a large construction wall which would ordinarily lead to shade and a degradation of the output. To mitigate the problem of energy lost due to shade, Tigo TS4-A-O optimizers were deployed to ensure the best possible system performance. "As
93rd Vifor Pharma Group Annual General Meeting6.5.2021 19:00:00 EEST | Press release
Regulatory News: At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 pandemic and in accordance with Ordinance 3 on measures to combat the coronavirus issued by the Swiss Federal Council, on the basis of Art. 8 of the new COVID-19 Act, shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 61.6% of the share capital was represented. Shareholder approvals Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd., as well as the consolidated Financial Statements of Vifor Pharma Group for 2020 by a large majority. The maximum possible 2022 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2020 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom